Circulating tumor DNA is a prognostic marker of tumor recurrence in stage II and III colorectal cancer: multicentric, prospective cohort study (ALGECOLS)-Reference-Cited by-同舟云学术

Circulating tumor DNA is a prognostic marker of tumor recurrence in stage II and III colorectal cancer: multicentric, prospective cohort study (ALGECOLS)

Published:2021-12 Issue: Volume:159 Page:24-33
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Benhaim Leonor^ORCID,Bouché Olivier,Normand Corinne,Didelot Audrey,Mulot Claire,Le Corre Delphine,Garrigou Sonia,Djadi-Prat Juliette,Wang-Renault Shu-Fang,Perez-Toralla Karla,Pekin Deniz,Poulet Geoffroy^ORCID,Landi Bruno,Taieb Julien,Selvy Marie,Emile Jean-Francois,Lecomte Thierry,Blons Helene^ORCID,Chatellier Gilles^ORCID,Link Darren R.^ORCID,Taly Valerie^ORCID,Laurent-Puig Pierre^ORCID

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference36 articles.

1. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods;Ferlay;Int J Cancer,2019

2. Revised TN categorization for colon cancer based on national survival outcomes data;Gunderson;J Clin Oncol Off J Am Soc Clin Oncol,2010

3. Early evaluation of circulating tumor DNA as marker of therapeutic efficacy in metastatic colorectal cancer patients (PLACOL study);Garlan;Clin Cancer Res Off J Am Assoc Cancer Res,2017

4. Circulating tumor cells and circulating tumor DNA detection in potentially resectable metastatic colorectal cancer: a prospective ancillary study to the unicancer prodige-14 trial;Bidard;Cells,2019

5. Circulating tumour DNA for monitoring colorectal cancer-a prospective cohort study to assess relationship to tissue methylation, cancer characteristics and surgical resection;Symonds;Clin Epigenet,2018

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A novel risk classification model integrating CEA, ctDNA, and pTN stage for stage 3 colon cancer: a post hoc analysis of the IDEA-France trial;The Oncologist;2024-07-15

2. Use of Circulating Tumor DNA to Guide Decision-making in Adjuvant Colon Cancer;Current Oncology Reports;2024-06-06

3. Clinical impact of circulating tumor DNA to track minimal residual disease in colorectal cancer patients. Hopes and limitations;ESMO Gastrointestinal Oncology;2024-06

4. Increased blood draws for ultrasensitive ctDNA and CTCs detection in early breast cancer patients;npj Breast Cancer;2024-05-15

5. Circulating tumour DNA-Based molecular residual disease detection in resectable cancers: a systematic review and meta-analysis;eBioMedicine;2024-05